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Abstract

Many individuals have been previously exposed to human adenovirus serotype 5 (Ad5). This prior immunity
has long been known to hinder its use for gene therapy and as a gene-based vaccine. Given these immunogenicity problems, we have tested whether polyethylene glycol (PEG) can blunt immune effects against Ad5
during systemic and mucosal vaccination. Ad5 vectors were covalently modified with 5-, 20-, and 35-kDa linear PEG polymers and evaluated for their ability to produce immune responses against transgene antigen products and the vector itself. We show that shielding Ad5 with different-sized PEGs generally reduces transduction and primary antibody responses by the intramuscular or intranasal route. In contrast, PEGylated vectors
generally appear better at boosting antibody responses in Ad-immune animals. Displaying either glucose or
galactose on PEG mediated increased transduction and antibody responses by the intranasal, but not the intramuscular, route. In naive animals, PEGylated vectors generated T cell responses that were equal to or better than those by unmodified Ad. Priming by PEGylated vectors generally enabled better subsequent T cell responses after boost. Priming and boosting by PEGylated vectors produced T cell responses after boost that were
equal to or higher than those produced by unmodified vectors. These data indicate that PEGylation can enable
more effective application of Ad5 and perhaps other Ad serotype vaccines during prime–boost vaccination.

Overview Summary

Introduction

Adenovirus is one of the most common viral vectors
used in gene therapy and viral vector vaccine trials to
date. However, there are considerable obstacles to the
use of these vectors in vivo. One of these obstacles is
the production of neutralizing antibody and cellular
immune responses against the vector. These responses
may not only reduce vector and vaccine efficacy, but
may also perturb the immune system, making vaccinees more susceptible to infection by HIV-1. In this paper, we examined the ability of polyethylene glycol
(PEG) to shield Ad5-based vectors from immune responses in the context of both systemic and mucosal
vaccination. We found that although PEG blunted bulk
transduction, it was particularly useful in prime–boost
vaccination of mice.

A

DENOVIRAL (Ad) VECTORS are arguably one of the most
potent gene delivery vectors for systemic and mucosal
immunization (Lubeck et al., 1997; Xiang et al., 1999; Barouch
et al., 2004; Gomez-Roman et al., 2006). The attraction for the
use of Ad viruses as gene delivery vectors stems from their
ability to transduce a wide range of dividing and nondividing cell types in some cases to efficiencies of nearly 100%.
Additional benefits include their stability, the ability to purify the vector to concentrations of up to 1013 particles/ml,
and the fact that viral vectors self-assemble into particles of
specific size (120 nm).
The immune system has evolved to repel infectious agents.
It is therefore not surprising that immune responses are
elicited against many of the gene-based vaccine vectors used
to deliver antigens. Although Ad vectors are potent for mediating gene delivery, they also have the reputation for be-
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ing one of the most immunogenic vectors for gene therapy
(Fields et al., 2000). Both innate and adaptive immune responses can be elicited by Ad capsid proteins and against
the transgene protein to attenuate antigen delivery and expression (Yang et al., 1994; Schnell et al., 2001).
Injection of naked Ad virions also produces robust neutralizing antibody responses against viral capsid proteins
that can bind and inactivate the virus. These neutralizing antibodies are generally serotype specific and are generally directed against the hypervariable regions of the hexon protein (Crawford-Miksza and Schnurr, 1996; Roberts et al.,
2006). Neutralizing antibodies are produced during natural
infection or after one inoculation of the vector into a naive
host. These preexisting or vector-induced antibodies are
problematic for an Ad-based vaccine as they can attenuate
the level of gene delivery if the same serotype of Ad is used
(Croyle et al., 2001).
Whereas anti-Ad antibodies and/or T cell responses can
attenuate vaccine efficacy, prior immunity to Ad (or any vaccine vector) may also have unexpected consequences. For example, in the STEP HIV vaccine trial, Ad serotype 5 (Ad5)based vectors were used to vaccinate non-HIV-infected
individuals. Rather than reducing HIV infection, preliminary
analysis of vaccinees found a higher than expected rate of
infection as compared with control subjects (Sekaly, 2008).
More troubling was the preliminary correlation between increased HIV infection rates and higher levels of preexisting
neutralizing antibodies against Ad5. These data suggest that
prior immunity to Ad and any virus-vectored vaccine may
not only attenuate efficacy, but may also create unexpected
immunological consequences. Therefore, approaches to reduce the production of antivector immune responses and to
shield vectors from existing immune responses may have
utility for increasing vaccine efficacy and safety.
Polyethylene glycol (PEG) is a clinically approved polymer used to improve the pharmacokinetics of a variety of
protein therapeutics. PEG has also been chemically conjugated to free amine groups on the Ad5 virion surface. PEG
has been shown to reduce a number of dangerous side effects caused by intravenous injection of Ad5 (Croyle et al.,
2005; Mok et al., 2005; Hofherr et al., 2007). For example, PEGylation of Ad5 reduces innate immune responses against
the vector as evidenced by 75% reduction in interleukin (IL)6 levels at 6 hr and 90% reduction in cumulative IL-6 over
48 hr (Mok et al., 2005). PEGylation also blunts thrombocytopenia, platelet activation, and endothelial activation after
intravenous injection (Croyle et al., 2005; Hofherr et al., 2007).
PEG also reduces uptake of the virus in macrophages and
Kupffer cells (Mok et al., 2005), consistent with the ability of
the polymer to reduce the production of new antibody and
cellular immune responses against Ad (Croyle et al., 2001).
PEGylation of Ad has also been shown to protect the vector from preexisting neutralizing antibodies to allow multiple administration into Ad-immunized or passively immunized recipients (O’Riordan et al., 1999; Croyle et al., 2001,
2002). In mice previously exposed to Ad5, readministration
of naked Ad resulted in up to a 10 million-fold reduction in
transduction (O’Riordan et al., 1999; Croyle et al., 2002). When
Ad was PEGylated with small (3- to 5-kDa) PEG, transduction was increased from 100- to 10,000-fold, suggesting this
approach could be a viable alternative to serotype switching
to allow Ad to be applied in the face of preexisting or vec-
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tor-induced antibodies. Although promising, it should be
noted that this rescue of transduction did not bring gene expression levels back to those occurring in naive mice. Instead,
transduction levels by intravenous routes were still 100- to
10,000-fold lower than those in unimmunized mice. A more
recent study compared the use of 5- and 20-kDa PEG for
transduction and for immunization (Wortmann et al., 2008).
Mice were passively immunized by transfer of serum from
Ad-immunized mice and then injected with unmodified or
20-kDa-PEGylated Ad expressing hepatitis B surface antigen.
In this case, passively transferred antibodies reduced immune responses against the hepatitis antigen by 84% as compared with unmodified vector. In contrast, the PEGylated
vector produced only a 33% reduction in immune responses
(Wortmann et al., 2008).
These data suggest that PEGylation of Ad may have some
ability to shield Ad vaccines from preexisting immune responses. However, in the gene therapy realm, PEGylation
has been shown to markedly reduce virus uptake into antigen-presenting cells (Croyle et al., 2005), making it uncertain
whether this shielding modification will allow productive
vaccine responses or will also reduce immune responses
against transgene production. Previous work tested the effects of PEG only on immunization in the systemic compartment (Wortmann et al., 2008). It was therefore also unclear how different-sized PEGs might affect transduction by
systemic and mucosal routes of vaccination. It was unclear
how much protection would be mediated by different-sized
PEGs in the context of a prime–boost regimen and by different routes of immunization.
This study has tested these parameters in mouse models,
using reporter gene imaging combined with neutralizing antibodies and antibody and cellular immune assays against
transgene products and HIV-1 antigens. We compare the effects of 5-, 20-, and 35-kDa PEG on transduction and immune
responses mediated by Ad5 after systemic immunization by
the intramuscular route and after mucosal immunization by
the intranasal route. These tests have been performed in both
naive and Ad-immunized mice to assess the actual utility of
PEGylation as a means to shield Ad vaccines against preexisting and vector-induced immune responses. We also test
the effects of appending carbohydrate ligands on the ends
of PEG to determine whether targeting cell surface lectins
may modulate vaccine effects.
Materials and Methods
Adenoviruses
First-generation replication-defective (E1/E3 deleted) Ad5
vectors were constructed with the AdEasy system (Statagene, La Jolla, CA) in 293A cells as described by Mok and
coworkers (2005). Ad-LIG expresses a firefly luciferase IRES
(internal ribosomal entry site) hrGFP (humanized Renilla
reniformis green fluorescent protein) cassette from the cytomegalovirus (CMV) promoter. Ad-GL expresses an enhanced GFP (eGFP)–luciferase fusion gene and Ad-gag expresses the HIV-1 p55gag codon-optimized gene of strain
HXB2 (Ad-gag). Both Ad-LIG and Ad-GL can be used for luciferase imaging. Neither the luciferase nor the hrGFP protein has useful T cell epitopes for enzyme-linked immunospot (ELISPOT) testing (data not shown). In contrast,
both Ad-GL and Ad-gag have H-2Kd-restricted epitopes that

PEG-SHIELDED ADENOVIRAL VECTORS
can be used to monitor T cell responses in BALB/c mice. All
adenoviruses were purified by CsCl banded and quantitated
by determining the optical density at 260 nm (OD260).
Animals
Female BALB/c mice (6–8 weeks old) were purchased
from Charles River Laboratories (Wilmington, MA) and
housed in the Mayo Clinic (Rochester, MN) animal facility
under the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC, Frederick,
MD) guidelines with animal use protocols approved by the
Mayo Clinic Animal Use and Care Committee. All animal
experiments were carried out according to the provisions of
the Animal Welfare Act, PHS Animal Welfare Policy, the
principles of the NIH Guide for the Care and Use of Laboratory
Animals, and the policies and procedures of Mayo Clinic.
Mice were immunized intramuscularly or intranasally.
Mice immunized intramuscularly received 1  1010 viral
particles (VP)/mouse in 25 l injected into the right quadriceps. Mice immunized intranasally received 1  1010
VP/mouse in 20 l (using 10 l/nare) delivered under ketamine–xylazine anesthesia. Where indicated, the mice were
boosted as described for priming. Two weeks after the boost,
the mice were bled and killed, and spleens were collected.

1371
NaCl, and 20 mM EDTA). Both supernatant and cell lysate
were subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) and transferred onto a nitrocellulose membrane (0.45-m pore size; Bio-Rad, Hercules, CA). After blocking the membrane with 1.0% bovine
serum albumin fraction V in DPBS (10 mM Tris-HCl [pH 7.5],
150 mM NaCl) for 1 hr at room temperature, the membranes
were washed three times with TBS-T (TBS containing 0.1%
Tween 20), reacted with an anti-HIV-1 Gag monoclonal
serum at a dilution of 1:1000 for 1 hr at room temperature,
and then incubated with horseradish peroxidase-conjugated
goat anti-mouse (Pierce Biotechnology, Rockford, IL) for 1
hr at room temperature. Protein bands were detected with
SuperSignal West Pico substrate (Pierce Biotechnology) and
imaged with a Kodak In Vivo imaging system F (Carestream
Health, Rochester, NY).
In vivo transduction
Cells were grown in a 96-well black plate (3603; Corning
Life Sciences, Lowell, MA). Virus (each at 104 VP/cell) was
added and incubated for 20 hr at 37°C and luminescence was
measured with a Beckman Coulter DTX 880 multimode detector as described in Hofherr and coworkers (2008). The percent transduction was determined as compared with unmodified virus.

Adenoviral PEGylation
For this study, we used succinimide-activated, amine-reactive PEG molecules of 5 kDa (Sunbright ME-050-HS; NOF,
Tokyo, Japan) and 20 and 35 kDa (m-SCM-35K; JenKem
Technology, Beijing, China). The 35-kDa PEG was used with
and without galactose or glucose moieties as potential ligands for carbohydrate receptors. Ad-GL, Ad-LIG, and Adgag were modified with the 5-, 20-, and 35-kDa PEGs and
with 35-kDa PEG-Gal and 35-kDa PEG-Glu polymers. All
PEGylation was performed as previously described (Hofherr
et al., 2007, 2008). Briefly, PEGylation was performed at room
temperature for 1 hr and excess nonreactive PEG was removed by gel filtration with Sephadex G100 (GE Healthcare
Life Sciences, Piscataway, NJ). The concentration of virus
was determined by absorbance at 260 nm and confirmed by
real-time polymerase chain reaction (PCR) as described in
Mok and coworkers (2005).
Quantitation of free amines
Free amines were determined with a CBQCA protein
quantitation kit (Invitrogen, Carlsbad, CA) as described in
Hofherr and coworkers (2008). Briefly, viruses were diluted
in phosphate-buffered saline (PBS), and KCN and 3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) were
added for 1 hr. Fluorescence emission was detected at 550
nm with excitation at 465 nm, using a DTX 880 multimode
detector (Beckman Coulter, Fullerton, CA). The percentage
of free amines was determined relative to a standard curve
of unmodified virus.
Western blot analysis
Ad-gag, modified and unmodified, was incubated with
A549 cells at 25,000 VP/cell for 24 hr. Cells and supernatant
were collected and lysed with lysing buffer (50 mM Tris-HCl,
1% Triton X-100, 0.15% sodium dodecyl sulfate, 150 mM

Particle sizing
Particle sizing was performed as described in Hofherr and
coworkers (2008), using a 90Plus/BI-MAS multiangle particle sizer (Brookhaven Instruments, Holtsville, NY). Particle
sizes are shown as the mean of three 3-min runs and standard error. Polydispersity was calculated and is proportional
to the variance of the intensity-weighted diffusion coefficient
distribution. Molecular weights were calculated according to
the Mark–Houwink–Sakurada equation.
In vivo luciferase imaging
Luciferase-expressing viruses Ad-LIG or Ad-GL were administered as indicated elsewhere in text and the mice were
imaged at various times with a MAG Biosystems Lumazone
imaging system (Photometrics, Pleasanton, CA) as described
by Hofherr and coworkers (2008). Mice were anesthetized
with isoflurane and injected intraperitoneally with D-luciferin (20 mg/ml in PBS) in a volume of 200 l; the mice
were then immediately placed into the Lumazone imager
and images were captured. All images were taken with a 10min exposure and 2  2 binning, using no filters and no photomultiplication. Data analysis was performed on each image, using background subtracted mean intensities detected
by the Lumazone imaging software at each time point, and
graphed with Prism graphing software (GraphPad Software,
San Diego, CA).
Adenovirus neutralization assay
Adenovirus-neutralizing antibodies (NAbs) were determined as previously described (Sprangers et al., 2003).
Briefly, sera were heat inactivated at 56°C for 30 min before
a serial doubling dilution was performed in a 96-well black
plate (3603; Corning Life Sciences). Sera were diluted from
1:20 to 1:2560 in a volume of 50 l of complete Dulbecco’s
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modified Eagle’s medium (DMEM) containing unmodified
Ad-LIG or Ad-GL at 1  108 VP/ml. Naive mouse serum
was used as negative control and was the maximal luciferase activity reference. The plates were incubated at 37°C for
1 hr. Fifty microliters of A549 cells at 1  105 cells/ml was
added to each well. Plates were incubated for 20 hr at 37°C
and 5% CO2 before readout. Luciferase activity was determined with 5 reporter lysis buffer and luciferase assay
reagent (LAR) (Promega, Madison, WI) as described in the
manufacturer’s protocol. Briefly, 25 l of 5 lysis buffer was
added to each well, mixed, and frozen at 80C. The plates
were thawed at room temperature and 50 l of LAR was
added. Each plate was shaken on an orbital shaker and luciferase activity was measured with a Beckman Coulter DTX
880 multimode detector. Neutralizing antibody titers were
determined as the reciprocal dilution to inhibit 90% of luciferase activity and are expressed as the geometric mean titer
(GMT).
Enzyme-linked immunospot assay
To measure cellular responses to eGFP and Gag, splenocytes were incubated in the presence of peptides at a concentration of 5 g/ml. To measure GFP responses the HYLSTQSAL peptide was used. Gag cytotoxic T lymphocyte (CTL)
and helper T cell responses were determined with the VGGHQAAMQMLKDTINEEAA peptide and peptide pool
(ATLEEMMTACQGVGGPSHKA,
TSNPPIPVGDIYKRWIILGL, and FKTLRAEQATQEVKNWMTDT), respectively.
Spleens from individual mice were minced and then forced
through a 40-m Nylon cell strainer (BD Biosciences, San Jose,
CA). Single-cell suspensions of splenocytes were plated in 96well polyvinylidene difluoride-backed plates (MultiScreen-IP;
Millipore, Billerica, MA) coated with 50 l of anti-mouse interferon (IFN)- monoclonal antibody (mAb) (AN18, 5 g/ml;
Mabtech, Stockholm, Sweden) and kept overnight at 4°C. The
plates were blocked with HEPES-buffered complete RPMI
medium at 37°C for 2 hr. Equal volumes (50 l) of each peptide pool and splenocytes (107 cells/ml) were added to the
wells in duplicate. Plates were incubated overnight (14 to 16
hr) at 37°C with 5% CO2. After the plates were washed six
times with PBS, 50 l of 1:1000-diluted biotinylated antimouse IFN- mAb (Mabtech) was added to each well. Plates
were incubated at room temperature for 2 hr and then washed
three times with PBS. Fifty microliters of streptavidin–alkaline phosphatase conjugate (1:1000 dilution; Mabtech) was
added to each well. After incubation at room temperature for
1 hr, the plates were washed five times with PBST. Finally,
100 l of BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium) Plus alkaline phosphatase substrate (Moss, Pasadena, MD) was added to each well. The
plates were incubated at room temperature for 10 min. After
washing with water, the plates were air dried. Spots were
counted with an automated ELISPOT plate reader (Immunospot counting system; CTL, Cleveland, OH) and expressed as spot-forming cells (SFCs) per 106 splenocytes.
Results
In vivo activity of PEGylated adenoviral vectors
Previous data have shown that PEGylation of Ad5 ablates
the ability of the virus to infect cells via the coxsack-
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ievirus–adenovirus receptor (CAR) (Ogawara et al., 2004).
However, after intravenous injection, 5-kDa PEG still allowed the vector to transduce the liver whereas 20- and 35kDa PEG blocked this transduction (Hofherr et al., 2008), perhaps by increasing viral particle size. The effects of PEG on
the tropism of Ad administered by the intravenous and intraperitoneal routes were tested in this previous work. Intramuscular and intranasal routes, relevant to systemic and
mucosal immunization, were not tested. In addition, the effects of PEG on immune responses against the virus and its
transgene products were also not tested.
To test the effects of PEGylation on vaccination, Ad-LIG
was modified with amine-reactive 5-, 20-, or 35-kDa PEG as
described in Hofherr and coworkers (2007, 2008) to produce
Ad-LIG-5K, Ad-LIG-20K, and Ad-LIG-35K. Reactive PEG
molecules are also available that display galactose or glucose
on their end. These PEG molecules were also tested, because
there are carbohydrate-binding receptors on immune cells
and mucosa. For example, galactose moieties can target gene
delivery to monocytes and dendritic cells via their mannose
receptor (Erbacher et al., 1996; Parrott et al., 2003). Similarly,
transfection of airway epithelial cells can be increased by targeting with glucose or galactose (Fajac et al., 1999). 35K PEGgalactose and 35K PEG-glucose were therefore also tested on
Ad-LIG (Ad-LIG-35K-Gal and Ad-LIG-35K-Glu) to determine whether appending either ligand on the PEG shield
would mediate increased immune responses.
Each PEGylated virus was characterized in vitro to determine the extent of PEGylation and the inhibition of in vitro
activity. PEGylation of all the reagents resulted in conjugation of 65 to 75% of the free amines on the viral surface as
determined by the CBCQA assay. Consistent with previous
work, PEGylation reduced in vitro transduction by 99%
(Table 1). Pretreatment of the viruses with mouse serum for
1 hr did not increase this transduction, suggesting that the
PEG coating was stable in biological fluids. Viral diameter
increased from 111 to 158 nm with the various PEG molecules. The predicted molecular weight of the modified adenoviruses increased up to two times that of unmodified Ad
(Table 1).
In vivo luciferase activity
Groups of five BALB/c mice were immunized on day 0
by the intramuscular and intranasal routes with 1  1010 viral particles (VP) of PEGylated and unmodified Ad. The mice
were then imaged for luciferase activity on days 1, 3, 5, and
12 after administration (Fig. 1). Introduction of unmodified
Ad generated robust luciferase activity by both the intramuscular and intranasal routes. Intramuscular injection of
Ad-LIG-5K bearing 5-kDa PEG produced signal primarily in
the injection site, but with some signal from the abdomen
(Fig. 1A). On the basis of previous imaging, this signal is consistent with expression in the liver (Hofherr et al., 2007, 2008).
This suggests that some 5K PEG-modified Ad virus translocated from the muscle injection site into the blood and mediated some level of liver transduction. Intranasal injection
generated luciferase activity primarily in the nasal region,
but with some activity observed in the lungs, particularly for
the unmodified virus (Fig. 1A).
Quantitation of luciferase activity by measurement of photons per second showed differing kinetics of bulk transgene

0.0
100.00
111.7  0.500
0.031  0.012
3.7
100.0

64.96
0.18
132.7  0.700
0.019  0.013
5.49
0.14

Abbreviations: PEG, polyethylene glycol; MW, molecular weight.
aAs measured by the CBCQA assay.
bAs determined using the Mark–Houwink–Sakurada equation.
cVirus was incubated with normal mouse serum for 1 hr at 37°C before infection.

Percent of PEG-conjugated free aminesa
Percent transduction of A549 cells
Effective diameter (nm)
Polydispersity
Calculated MWb ( 107 g/ml)
Percent activity after serum treatmentc

Ad-LIG-5K

IN VITRO CHARACTERIZATION

Ad-LIG

TABLE 1.
OF

70.54
0.01
145.9  1.200
0.049  0.021
6.88
0.00

Ad-LIG-20K

74.41
0.02
158.5  1.50
0.93  0.023
8.35
0.06

Ad-LIG-35K
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72.07
0.02
150.5  2.700
0.044  0.020
7.40
0.06

Ad-LIG-35K-Gal

69.70
0.01
153.9  2.500
0.077  0.001
7.79
0.17

Ad-LIG-35K-Glu
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FIG. 1. In vivo luciferase activity induced by unmodified and PEGylated Ad-LIG after intramuscular and intranasal immunization. Groups of five mice were administered 1010 VP of the indicated vectors by the indicated routes. Twentyfour hours later the animals were anesthetized, injected with luciferin, and imaged for luciferase activity (A). Mice were
imaged on days 1, 3, 5, and 12. The luciferase activity for intramuscularly and intranasally immunized mice is shown in
panel A. Graphs reflect luciferase activity from the entire mouse. Error bars represent the standard error.
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These data show that PEGylated Ad5 vectors can generate antibody responses against transgene products. Because
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Preboost
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Five weeks after priming, the groups of mice from Figs. 1
to 3 were boosted with the same vector by the same route as
was used for priming (e.g., intranasal Ad-LIG-5K and then
intranasal Ad-LIG-5K, etc.). Two weeks after boost, anti-luciferase antibodies were again measured. When the intramuscularly injected mice were boosted, unmodified Ad did
not further boost luciferase antibody levels. In contrast, all
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Effect of PEG on production of anti-luciferase antibodies
in the face of preexisting immunity
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Previous work has suggested PEG may shield Ad from
neutralizing antibodies and reduce the production of new
immune responses against the virus (O’Riordan et al., 1999;
Croyle et al., 2001, 2002; Wortmann et al., 2008). To test this,
serum Ad-neutralizing antibodies were assayed 3 weeks after priming (Fig. 3). Intramuscular or intranasal injection of
unmodified or PEGylated Ad produced geometric mean
titers (GMTs) of Ad-neutralizing antibodies of less than 100.
PEGylated Ad did not reduce the induction of neutralizing
antibodies (Fig. 3A). Interestingly, neutralizing antibodies by
the 5-kDa PEGylated virus in the intranasal group were 2fold lower than those generated by unmodified Ad (p  0.01
by ANOVA with Bonferroni post-hoc test) (Fig. 3B).

B
i.n. Anti-Luciferase Activity (OD450)

Effect of PEGylation on induction of primary antibody
responses against adenoviral vector
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Serum was collected from mice 3 weeks after immunization and antibodies against luciferase were measured by enzyme-linked immunosorbent assay (ELISA) (hrGFP protein
was unavailable for this test). By the intramuscular route antibody responses were highest with unmodified Ad (Fig. 2A).
By the intranasal route antibody responses were highest with
unmodified Ad and lowest for viruses modified with 5- or
20-kDa PEG (Fig. 2B). Ad-LIG modified with any of the 35kDa PEGs generated antibody responses that were nearly as
strong as that with unmodified Ad. These antibody data generally correlated with cumulative luciferase expression
(Fig. 1) and the AUC calculations.

Effect of PEGylation on induction of cellular immune
responses in the absence of previous exposure
to adenovirus

Ad

Effect of PEGylation on primary antibody responses
against transgene product

of the PEGylated vectors boosted, with most luciferase antibody levels approaching the same level as those generated
by unmodified Ad (Fig. 2A). When the intranasally injected
mice were boosted with the same vectors, anti-luciferase antibodies increased in all groups except the 5- and 20-kDa PEG
groups (Fig. 2B). These data suggest that the PEGylated vectors mediated transduction in the face of neutralizing antibodies to boost anti-transgene immune responses. The lack
of boosting by unmodified Ad by the intramuscular route
may be due to vector neutralization.

i.m. Anti-Luciferase Activity (OD450)

expression (Fig. 1B and C). Modification of Ad with all of
the PEGs reduced transduction by the intramuscular route
from 50 to 90% on day 1 and beyond. Expression was highest on day 1 and this expression decayed for all the vectors
over 12 days (Fig. 1B). The kinetics of expression by the intranasal route was markedly different from that by the intramuscular route (Fig. 1C). In this case, expression by most
vectors peaked on day 1, but remained relatively high for 5
days. In contrast, expression by Ad-LIG-35K-Gal and -Glu
(bearing galactose and glucose ligands) peaked on day 5 and
was higher than with the other vectors. Area under the curve
(AUC) calculations for intranasal luciferase expression
showed that viruses modified with 5- or 20-kDa PEG produced approximately 50% expression compared with unmodified Ad. Ad modified with 35-kDa PEG generated
nearly equal AUC as compared with unmodified Ad. Viruses
modified with 35-kDa PEG-Gal and 35-kDa PEG-Glu had
AUCs that were approximately 3- and 2-fold higher than that
of unmodified Ad, respectively (data not shown).
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FIG. 2. Anti-luciferase antibody responses after priming
and boosting. Sera from the mice in Fig. 1 were collected before and after boosting with the same indicated vector and
were tested by ELISA against luciferase protein. Data are
shown for immunization by the intramuscular (A) and intranasal (B) routes. Data represent the means of five animals
and error bars represent the standard error.
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there are no known H-2Kd T cell epitopes in either the luciferase or Renilla GFP transgenes, an alternative Ad5 vector, Ad-GL, was used to assess cellular immune responses.
Ad-GL expresses the GFPLuc fusion protein of the codonoptimized Aequorea victoria green fluorescent protein and
firefly luciferase. Unlike Renilla GFP, this jellyfish GFP protein bears a known H-2Kd-restricted peptide, HYLSTQSAL,
that can be used to test CD8 T cell responses in BALB/c
mice (Andersson and Barry, 2004; Andersson et al., 2005). Luciferase imaging of Ad-GL demonstrated that it can also be
used for luciferase imaging, but has lower activity and a
shorter time course of detection than Ad-LIG (Fig. 4A).
Ad-GL was PEGylated with either 5- or 35-kDa PEG (Table
2) and groups of 20 BALB/c mice were immunized with either buffer, Ad-GL, Ad-GL-5K, or Ad-GL-35K. Luciferase
imaging 1 day after injection revealed that transduction by
Ad-GL-5K was 60 to 80% lower than by unmodified Ad via
the intramuscular and intranasal routes (p  0.001 by
ANOVA; Fig. 4B and C). Transduction by Ad-GL-35K was

25 to 60% lower than by Ad via both the intramuscular and
intranasal routes (p  0.05). These data are similar to the day
1 data from Ad-LIG in Fig. 1B and C, with the exception that
Ad-LIG expression was not significantly different from that
of Ad-LIG-5K and Ad-LIG-35K. The difference between the
two vectors may be due to the lower and shorter persistence
of luciferase expression by Ad-GL versus Ad-LIG (Fig. 4A).
Serum samples were collected 3 weeks after priming with
Ad-GL. All vectors generated Ad-neutralizing titers greater
than 50 by the intramuscular route (Fig. 5A). The highest levels were produced by the 35-kDa PEG-modified vector and
the lowest by the 5-kDa PEGylated vector. By the intranasal
route, both unmodified and 35-kDa PEG-modified Ad generated high levels of anti-Ad antibodies (Fig. 5B). In contrast,
the 5-kDa PEGylated vector produced 4-fold lower neutralizing antibodies (p  0.01 for both by ANOVA). These data
are consistent with neutralizing antibodies generated by AdLIG (Fig. 3).
Five weeks after priming with buffer or Ad-GL, each
group of 20 mice was divided into groups of 5 and these
were boosted with either buffer, Ad-gag, Ad-gag-5K, or Adgag-35K by the same route as was used at priming (i.e., intranasal and then intranasal or intramuscular and then intramuscular). Two weeks after boost, the resulting T cell
immune responses against both transgenes were detected by
ELISPOT (Figs. 6 and 7). GFP T cell responses generated by
priming were measured 7 weeks after Ad-GL immunization
(Fig. 6A and B). Gag T cell responses generated at boost were
measured 2 weeks after Ad-gag immunization.
Figure 6 represents T cell responses against GFP and Gag
in mice that had no prior exposure to Ad. For GFP, this corresponds to all the mice that were primed originally. For Gag,
this corresponds to the mice that received only buffer at
priming (i.e., no virus) and then were immunized with Adgag vectors. Figure 7 represents T cell responses generated
against Gag in mice that were already immunized with AdGL, Ad-GL-5K, or Ad-GL-35K. Figure 7 therefore represents
how well each of the vectors mediates immunization in the
presence of preexisting anti-Ad immunity that was established during the original prime with each of the Ad vectors.
There were no statistically significant differences in T cell
responses against GFP between the vectors when they were
delivered intramuscularly into mice with no prior immunity
to Ad (n  20; Fig. 6A). By the intranasal route, Ad-GL-5K
generated significantly higher anti-GFP responses than both
unmodified Ad and the Ad-GL-35K (n  20; p  0.001) (Fig.
6B). This was interesting given that this vector also generated the lowest levels of neutralizing antibodies against Ad
by the intranasal route. Anti-Gag T cell responses in naive
mice were highest with the unmodified vector after intramuscular injection, but these responses were not significantly higher than those generated with the PEGylated virus
(n  5; Fig. 6C). By the intranasal route, Gag responses in
naive animals were all substantially lower than by the intramuscular route (n  5; Fig. 6D). The pattern of responses
after intranasal immunization against Gag was similar to
those against GFP. These were not significantly different,
perhaps because of the lower n value of the group, the lowlevel responses, or the increased resting time for GFP responses as compared with the Gag T cell responses (7 vs. 2
weeks, respectively).

100.0%
116.0  0.800
ND
ND
0.004  0.002
4.05

1.8%
129.5  0.900
ND
ND
0.007  0.002
5.21

Ad-GL-5K

IN VITRO CHARACTERIZATION

Abbreviation: ND, not determined.
aDetected by luminescence emission.
bDetermined by densitometry using Kodak In Vivo imaging system F software analysis.
cAs determined using the Mark–Houwink–Sakurada equation.

Luciferase activitya
Effective diameter (nm)
Gag expressionb
-Actin expressionb
Polydispersity
MWc ( 107 g/ml)

Ad-GL

TABLE 2.
OF

3.7%
149.8  1.000
ND
ND
0.061  0.017
7.23

Ad-GL-35K

AND

ND
109.4  0.700
100.0%
100.0%
0.012  0.007
3.53

Ad-gag

POLYETHYLENE GLYCOL-MODIFIED Ad-GL

Ad-gag

ND
122.3  1.900
0.0%
103.2%
0.036  0.027
4.54

Ad-gag-5K

ND
165.6  1.800
0.0%
95.4%
0.043  0.021
9.31

Ad-gag-35K

1378

WEAVER AND BARRY

B
Ad-GFPLuc

2.0 ⫻ 1010

2.0 ⫻ 1009

C
1.0 ⫻ 108

p ⬍ 0.05
p ⬍ 0.001

i.n. Luciferase Activity
(Photons/sec)

Ad-LIG

2.0 ⫻ 1011

i.m. Luciferase Activity
(Photons/sec)

i.m. Luciferase Activity
(Photons/sec)

A

p ⬍ 0.01

1.0 ⫻ 107

1.0 ⫻ 106

0 2 4 6 8 10 12 14 16 18 20 22

Ad-GL

Ad-GL
-5K

Day

1.0 ⫻ 108

p ⬍ 0.05
p ⬍ 0.001

p ⬍ 0.01

1.0 ⫻ 107

1.0 ⫻ 106

Ad-GL
-35K

Ad-GL

Ad-GL
-5K

Ad-GL
-35K

FIG. 4. In vivo luciferase activity induced by unmodified and PEGylated Ad. Mice were immunized with Ad-LIG and AdGL administered intramuscularly at 1010 VP. The mice were imaged over time and luciferase activity was plotted (A). (B
and C) Mice were administered 1010 VP of the indicated vectors by the indicated routes. Twenty-four hours later the animals were anesthetized, injected with luciferin, and imaged for luciferase activity. Quantitation of luciferase expression induced by unmodified and PEGylated Ad-LIG after intramuscular (B) and intranasal (C) immunization is shown. Data represent the mean luciferase activity from 20 mice. Error bars show the standard error associated with this mean. Statistical
analysis was performed by one-way ANOVA.

Effect of PEG modification on T cell responses
against Gag in the presence of preexisting
anti-adenoviral immunity

ther 5-kDa or 35-kDa PEG-modified Ad-gag produced antiGag T cell responses equal to or greater than those induced
in naive mice (Fig. 7E).

To test whether PEG could shield Ad vaccines from antibodies after systemic and mucosal immunization, animals
primed with unmodified and PEGylated Ad-GL were immunized with unmodified and PEGylated Ad-gag by the
same routes. T cell responses against Gag were assessed 2
weeks later (Fig. 7). Listed to the left of each panel is the
virus that was used for priming. The dotted line in each panel
shows the benchmark level of anti-Gag T cell responses generated in Fig. 6 with Ad-gag in naive mice. Each solid line
represents the anti-Gag T cell response induced by unmodified Ad-gag in mice with preexisting immunity, a real-world
example of virus-vectored vaccines.

Intranasal priming and boosting
T cell immune responses induced by intranasal immunization with Ad-gag, Ad-gag-5K, and Ad-gag-35K in the
presence of neutralizing antibodies are shown in Fig. 7B, D,
and F, respectively. Prior intranasal immunization with unmodified Ad generally resulted in lower T cell responses
than were generated by Ad-gag in naive mice (Fig. 7B). In
this case, PEGylation of Ad-gag afforded little protection
against neutralizing antibodies. In contrast, mice primed intranasally with Ad-GL-5K or Ad-GL-35K generally produced anti-Gag T cell responses equivalent to or higher than
responses generated with Ad-gag in naive mice (Fig. 7D and
F). The highest level of Gag T cell responses after intranasal
immunization was induced with the Ad-GL-5K/Ad-gag-35K
combination, possibly because of the use of heterologous
PEG (Fig. 7D).

Intramuscular priming and boosting
In mice preimmunized with unmodified Ad-GL, both the
Ad-gag-5K and Ad-gag-35K viruses induced higher T cell
responses against Gag than unmodified Ad-gag. Reciprocally, Gag T cell responses generated by Ad-gag were higher
in mice primed with Ad-GL-5K or Ad-GL-35K than in mice
primed with unmodified Ad-GL (Fig. 7C and E). In mice
primed with Ad-GL-5K, all Ad-gag vectors induced anti-Gag
T cell responses that were at least equal to those produced
in naive mice (Fig. 7C). Priming with Ad-GL-35K did not allow unmodified Ad-gag to generate as robust T cell responses. However, priming with Ad-GL-35K followed by ei-

One of the most common criticisms of using Ad as a viral
vector for vaccine development is the fact that, depending
on the region, 25–50% of the population has preexisting Ad
antibodies due to natural infection. These antibodies have
long been anticipated to blunt the ability of the vector to mediate efficient transduction and, by extension, efficient im-
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FIG. 6. Cellular immune responses mediated by unmodified
and PEGylated Ad immunization of naive mice. Anti-GFP T
cell responses 7 weeks after intramuscular and intranasal immunization were measured by ELISPOT and are shown in (A)
and (B) (n  20). Anti-Gag ELISPOT responses 2 weeks after
intramuscular and intranasal immunization are shown in (C)
and (D) (n  5). Bars indicate the standard error.
munization against the transgene product. An additional
negative role for preexisting immune responses against Ad
has been speculated in the failure of the anti-HIV STEP trial,
in which higher levels of anti-Ad immunity appeared to increase the likelihood of infection with HIV, rather than prevent it (Sekaly, 2008). Given these issues, efforts to evade preexisting and vector-induced immunity to Ad5 and other
adenoviral vectors may be crucial in applying these as vaccines in humans.
We have investigated the use of PEG to modify or shield
Ad from preexisting or vector-induced immune responses
and to reduce the induction of new anti-vector immune responses. We show that the PEGylated viruses have significantly larger effective diameters and their predicted molecular weight has been increased up to 3-fold. PEGylated Ad
appears “dead” in vitro; however, the modified viruses are
capable of transduction and transgene expression as shown
by in vivo imaging. This dichotomy between in vitro and in
vivo transduction by PEGylated Ad is consistent with prior
observations of PEGylated Ad applied by intravenous and
intraperitoneal injection (Mok et al., 2005; Hofherr et al., 2007,
2008).
The effects of PEGylation were explored in the context of
performing systemic immunization by the intramuscular
route and by performing mucosal immunization by the intranasal route. Interestingly, the various PEG modifications
had different effects on Ad-mediated immune responses. By
the intramuscular route, all PEGs reduced transduction. This
reduced transduction correlated with reduced antibody responses against the luciferase protein product after priming.

Priming with all the vectors generated similar levels of antiAd neutralizing antibodies by the intramuscular route. After the second administration of unmodified Ad in the face
of these neutralizing responses, antibodies against luciferase
failed to boost. In contrast, boosting with the PEGylated vectors did boost luciferase antibody to levels similar to those
produced with unmodified Ad. These data suggest that
PEGylated vectors may evade these neutralizing responses
better than unmodified Ad, to retain a better ability to boost
immune responses. Alternatively, the lack of boost by unmodified Ad may be due to its having already achieved the
maximal level of anti-luciferase antibodies after priming. Or,
the high level of anti-luciferase antibodies in that group
might have quenched the boost by absorbing all released
antigen. Although these alternatives are possible, the relatively low antibody levels against luciferase suggest that
these explanations may not apply.
When T cell responses were monitored against GFP and
Gag after intramuscular immunization, the PEGylated vectors produced equal to slightly lower responses after priming compared with unmodified Ad. GFP T cell responses
measured from 20 animals were essentially identical by unmodified and PEGylated vectors by the intramuscular route.
These data suggest that lower transduction by the PEGylated
vectors may affect antibody responses, because these generally require large amounts of antigen delivered, but not
T cell responses, which may require a lower threshold of protein production for priming. When animals were boosted intramuscularly in the presence of anti-Ad immunity, the
PEGylated vectors generated superior T cell responses than
the unmodified vector. The simplest comparison is observed
in mice primed with unmodified Ad-GL. In this case of simple preexisting immunity to Ad5, 5-kDa PEG generated
higher anti-Gag T cell responses than either unmodified or
35-kDa PEG-modified Ad-gag viruses. Similarly, the 5-kDa
PEGylated vector appeared to be a better T cell-priming
agent by the intramuscular route and retained or generated
higher anti-Gag T cell responses regardless of which virus
was used for boosting. In summary for the intramuscular
route, PEGylation modestly reduced priming responses, but
5-kDa PEGylation appeared to be generally the most optimal modification for priming or boosting when more than
one immunization was performed.
Ad PEGylation had different effects when the viruses were
used for mucosal intranasal immunization. Priming with 5and 20-kDa PEGs generated weak transduction and weak
anti-luciferase antibody responses. This is consistent with
their effects on in vitro transduction and may be due to inhibition of CAR binding. This effect may be more pronounced by the intranasal route than by the intramuscular
route, because intranasal administration bathes the surface
of the mucosa with virus in a manner similar to that in a cell
culture dish. In contrast, intramuscular injection delivers the
virus under pressure and traps the virus in the enclosed muscle bed, where perhaps integrin interactions are enhanced by
the virus.
Modification of Ad with the “naked” 35-kDa PEG lacking
sugar moieties gave somewhat intermediate effects. It gave
similar to lower transduction after intranasal administration
than unmodified Ad 1 day after injection and its expression
did not increase over time, like the sugar-modified 35-kDa
PEGs. This intermediate expression profile reduced antibody
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priming, but was sufficient to give a better boost than the 5or 20-kDa PEG-modified vectors. The sugar-modified 35kDa PEGs, surprisingly, increased intranasal gene expression. These differences in expression correlated well with
anti-luciferase antibody responses. Priming antibody levels
generated by both 35K-Gal and 35K-Glu were similar to that

of unmodified Ad and boosting with Ad-35K-Glu generated
similar anti-luciferase antibodies as compared with unmodified Ad. The effects of the sugar moieties by the intranasal,
but not the intramuscular, route suggest they may affect vector targeting to antigen-presenting cells or mucosa (Erbacher
et al., 1996; Fajac et al., 1999; Parrott et al., 2003). Alternatively,

PEG-SHIELDED ADENOVIRAL VECTORS
they may affect vector stability or pharmacology. Given that
these sugar modifications overcome the deficiencies of the
unmodified PEGs after intranasal immunization, they merit
further testing.
When T cell responses were explored after intranasal immunization, priming responses were equal to or higher for
PEGylated vectors versus unmodified Ad despite the fact
that this modification reduced transduction and antibody responses. This could again be due a lower threshold of antigen expression being needed to prime T cell versus antibody
responses. After priming with unmodified Ad, the PEGylated vectors were, surprisingly, less able to generate antiGag responses by the intranasal route. It is possible that the
combination of reduced CAR binding and neutralization
may simply push transduction below the needed threshold
of T cell priming. In contrast, when the 5-kDa PEGylated vector was used for priming by the intranasal route, boosting T
cell responses with unmodified Ad-gag were as good as
those produced in naive mice. Indeed, priming with the 5kDa PEGylated Ad enabled all of the boosting vectors to generate anti-Gag T cell responses that were equal to or even
higher than those generated in naive animals. This effect may
be due to the significantly lower production of Ad-neutralizing antibody responses with the 5-kDa PEG. Whether 5kDa PEG effects extend to reducing anti-Ad T cell responses
remains to be demonstrated in a better model. Priming with
35K-modified Ad allowed T cell responses equal to those in
naive animals with all the vectors. These data suggest that
an optimal approach for intranasal immunization for T cell
responses may involve priming and boosting with the same
or different PEGylated vectors. It is possible that combined
PEGylation with 5 kDa PEG for shielding and sugar-targeted
PEGs on one vector may enhance both prime and boost immunization by the intranasal route.
Our attempts to test ELISPOT responses against Ad failed
with the peptides that were available. Therefore, it is unclear
whether prior immunization with Ad attenuates boosting because of effects on neutralizing antibodies or on Ad-directed
T cell responses. It is therefore possible that PEG may mediate its beneficial effects by protection against either antibody or T cell responses or both. Given the potential problem of vector-directed immune responses in the STEP trial,
teasing out the effects of PEG on these responses will be an
important area of exploration.
In summary, we have shown that PEGylation of Ad5 mediates significant boosting of antibody and T cell responses in
the face of prior immunity to Ad5. We also show that priming
with PEGylated vectors can enable unmodified and PEGylated
vectors to produce stronger immune responses than are produced after priming with unmodified Ad. On the basis of this,
PEGylation of Ad5 and other Ad serotypes may have utility
for immunoevasion, is applicable for use in vaccine development, and shows promise for readministration in naive animals, immune animals, and, perhaps, in humans.
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